中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 37 Issue 8
Aug.  2021
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2021  >  37(8): 1811-1816

Influence of virologic response on disease progression in patients with compensated hepatitis B cirrhosis

DOI: 10.3969/j.issn.1001-5256.2021.08.014
  • a.

    Department of Hepatology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China

  • b.

    Laboratory of Cellular Immunity, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China

Research funding:

National Natural Science Foundation of China (81874436);

National Natural Science Foundation of China (81774256);

Three-year Action Plan for Further Speed Up the Development of Chinese Medicine in Shanghai (ZY〔2018-2020〕-CCCX-2003-01);

National Science and Technology Major Project for the Prevention and Treatment of Major Infectious Diseases such as AIDS and Viral Hepatitis (2018ZX10725504);

Pilot Project of Clinical Collaboration Between TCM and Western Medicine for Major and Intractable Diseases (ZY〔2018-2020〕-FXTW-2004);

Traditional Chinese Medicine Consortium Construction Project in Shanghai Pudong New Area (PDZY-2019-0601)

  • Received Date: 2020-12-21
  • Accepted Date: 2021-02-18
  • Published Date: 2021-08-20
    Abstract
  •   Objective  To investigate the effect of sustained virologic response on disease progression and the development of hepatocellular carcinoma (HCC) in patients with compensated hepatitis B cirrhosis receiving antiviral therapy with nucleos(t)ide analogues (NAs).  Methods  A total of 542 patients with compensated hepatitis B cirrhosis who attended Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine from January 1 to December 31, 2013, received antiviral therapy, and were followed up for more than 5 years were enrolled, and according to the status of virologic response during follow-up, they were divided into a sustained virologic response cohort with 496 cases and a non-sustained virologic response cohort with 46 cases. With disease progression as the outcome event, general information and examination data were collected during the 5-year follow-up period. The t-test was used for comparison of normally distributed continuous data between groups, and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between groups; the chi-square test was used for comparison of categorical data between groups. A multivariate logistic regression analysis was performed; relative risk and 95% confidence interval (CI) were used to investigate the degree of correlation of factors measured with the progression of liver cirrhosis. The life-table method was used to calculate the 1-, 3-, and 5-year progression-free survival rates, and the Kaplan-Meier method was used to plot survival curves; the log-rank test was used for univariate analysis, and the Cox regression model was used for multivariate regression analysis.  Results  For the 542 patients, the mean progression-free survival time was 62.50 months (95% CI: 61.01-63.92), and the 1-, 3-, and 5-year progression-free survival rates were 94%, 82%, and 71%, respectively. The sustained virologic response cohort had a significantly longer mean progression-free survival time than the non-sustained virologic response cohort [63.10 months (95% CI: 61.65-64.55) vs 55.95 months (95% CI: 50.19-61.71), χ2=12.058, P=0.001]. Compared with the non-sustained virologic response cohort, the sustained virologic response cohort had significantly lower 5-year cumulative incidence rate of HCC than (20.6% vs 34.8%, χ2=5.759, P=0.016) and 5-year cumulative incidence rate of decompensated cirrhosis (5.0% vs 15.2%, χ2=8.239, P=0.004). Virologic response was an independent risk factor for disease progression (hazard ratio=2.32, 95% CI: 1.45-3.72).  Conclusion  Sustained virologic response can reduce the incidence rates of complications and HCC, improve long-term prognosis, and prolong survival time in patients with compensated hepatitis B cirrhosis.

     

    • FullText(HTML)
  • loading
    • References(12)
  • [1]
    Chinese Society of Infectious Diseases and Chinese Society of Hepatology, Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B: A 2019 update[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.

    中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
    [2]
    FATTOVICH G, BORTOLOTTI F, DONATO F. Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors[J]. J Hepatol, 2008, 48(2): 335-352. DOI: 10.1016/j.jhep.2007.11.011.
    [3]
    HOU JL, ZHAO W, LEE C, et al. Outcomes of long-term treatment of chronic HBV infection with entecavir or other agents from a randomized trial in 24 countries[J]. Clin Gastroenterol Hepatol, 2020, 18(2): 457-467.e21. DOI: 10.1016/j.cgh.2019.07.010.
    [4]
    Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B: A 2010 update[J]. J Clin Hepatol, 2011, 27(1): 113-128. http://lcgdbzz.org/article/id/LCGD201101035

    中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2010年版)[J]. 临床肝胆病杂志, 2011, 27(1): 113-128. http://lcgdbzz.org/article/id/LCGD201101035
    [5]
    Ministry of Health of the People's Republic of China. Diagnosis, management, and treatment of hepatocellular carcinoma (V2011)[J]. J Clin Hepatol, 2011, 27(11): 1141-1159. DOI: 10.3969/j.issn.1001-5256.2011.11.004.

    中华人民共和国卫生部. 原发性肝癌诊疗规范(2011年版)[J]. 临床肝胆病杂志, 2011, 27(11): 1141-1159. DOI: 10.3969/j.issn.1001-5256.2011.11.004.
    [6]
    WANG FS, FAN JG, ZHANG Z, et al. The global burden of liver disease: The major impact of China[J]. Hepatology, 2014, 60(6): 2099-2108. DOI: 10.1002/hep.27406.
    [7]
    CHEN YC, CHU CM, YEH CT, et al. Natural course following the onset of cirrhosis in patients with chronic hepatitis B: A long-term follow-up study[J]. Hepatol Int, 2007, 1(1): 267-273. DOI: 10.1007/s12072-007-5001-0.
    [8]
    ZHANG Y. The analysis of the risk factors for hepatocellular carcinoma in patients with hepatitis B virus cirrhosis receiving antiviral treatment[D]. Shenyang: China Medical University, 2018.

    张瑶. 接受抗病毒治疗的乙肝肝硬化患者进展为肝癌的危险因素分析[D]. 沈阳: 中国医科大学, 2018.
    [9]
    CHEN CJ, YANG HI, SU J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level[J]. JAMA, 2006, 295(1): 65-73. DOI: 10.1001/jama.295.1.65.
    [10]
    ZHANG MJ. Analysis and discussion on the effect of antiviral therapy for patients with decompensated cirrhosis of hepatitis B[J]. China Prac Med, 2018, 13(25): 5-7. DOI: 10.14163/j.cnki.11-5547/r.2018.25.003.

    张敏杰. 乙型肝炎肝硬化失代偿期患者抗病毒治疗效果分析与探讨[J]. 中国实用医药, 2018, 13(25): 5-7. DOI: 10.14163/j.cnki.11-5547/r.2018.25.003.
    [11]
    NAM JY, CHANG Y, CHO H, et al. Delayed viral suppression during antiviral therapy is associated with increased hepatocellular carcinoma rates in HBeAg-positive high viral load chronic hepatitis B[J]. J Viral Hepat, 2018, 25(5): 552-560. DOI: 10.1111/jvh.12838.
    [12]
    TERRAULT NA, LOK A, MCMAHON BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67(4): 1560-1599. DOI: 10.1002/hep.29800.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(4)  / Tables(6)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (445) PDF downloads(71) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return